Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Dec 2;138(22):2159-2160.
doi: 10.1182/blood.2021014195.

VITT(al) insights into vaccine-related clots

Jeffrey R Strich  1   2 , Yogendra Kanthi  3
Affiliations
Editorial

VITT(al) insights into vaccine-related clots

Jeffrey R Strich et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: Y.K. serves as a board member for the Society for Vascular Medicine, participates in the National Heart, Lung and Blood Institute (NHLBI) CONNECTS program and ACTIV-4 Host Tissue trial, and is an author on an unrelated patent application by the University of Michigan for the use of biogases in vascular disease. J.R.S. was the principal investigator of a clinical trial sponsored by the NHLBI to evaluate fostamatinib in acute COVID and participates in the ACTIV-4 Host Tissue trial.

Figures

None
Two-step process for VITT pathogenesis. (A) Shortly after vaccine administration, components of the adenovirus vaccine and PF4 generate immune complexes, whereas EDTA sequesters calcium, leading to vascular leak and an inflammatory response serving as a danger signal to provoke antibody generation. (B) One to 3 weeks after vaccine administration, polyanion/PF4/anti-PF4 antibody immune complexes trigger neutrophil extracellular trap formation and platelet aggregation in an FcγRIIA-dependent manner, resulting in thrombosis. Illustration by Alan Hoofring, National Institutes of Health.
See this image and copyright information in PMC

Comment on

  • Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia.
    Greinacher A, Selleng K, Palankar R, Wesche J, Handtke S, Wolff M, Aurich K, Lalk M, Methling K, Völker U, Hentschker C, Michalik S, Steil L, Reder A, Schönborn L, Beer M, Franzke K, Büttner A, Fehse B, Stavrou EX, Rangaswamy C, Mailer RK, Englert H, Frye M, Thiele T, Kochanek S, Krutzke L, Siegerist F, Endlich N, Warkentin TE, Renné T. Greinacher A, et al. Blood. 2021 Dec 2;138(22):2256-2268. doi: 10.1182/blood.2021013231. Blood. 2021. PMID: 34587242 Free PMC article.

References

    1. Greinacher A, Selleng K, Palankar R, et al. . Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood. 2021;138(22):256-2268. - PMC - PubMed
    1. Voysey M, Clemens SAC, Madhi SA, et al. ; Oxford COVID Vaccine Trial Group . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. - PMC - PubMed
    1. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S.. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092-2101. - PMC - PubMed
    1. Kelton JG, Warkentin TE.. Heparin-induced thrombocytopenia: a historical perspective. Blood. 2008;112(7):2607-2616. - PubMed
    1. Zuo Y, Yalavarthi S, Shi H, et al. . Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11):138999. - PMC - PubMed